Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3Cisplatin 3Letrozole 2Immune Checkpoint Inhibitors 2Imatinib Mesylate 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Carboplatin 2Azacitidine 2venetoclax 1trametinib 1toripalimab 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1semaglutide 1ruxolitinib 1rozanolixizumab 1rasburicase 1radium Ra 223 dichloride 1pyrotinib 1pirtobrutinib 1oxycodone-acetaminophen 1olutasidenib 1obinutuzumab 1nirogacestat 1niraparib 1nilotinib 1naldemedine 1idelalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Oxidoreductases × 30 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡